MMV at ASTMH 2008

8 - 10 April 2008
New Orleans, USA

MMV was involved in a number of sessions at the ASTMH in New Orleans.

View the list of all MMV symposia 


The Antimalarials market in Africa: Do we know enough? 

3:45 pm - 5:30 pm

MMV symposium session 53, Grand Ballroom D, Fifth Floor Sheraton New Orleans chaired by Co-chairs: Dr Ricardo Thompson National Institute of Research of Mozambique & Renia Coghlan, Medicines for Malaria Venture
Description: This symposium will share information on new initiatives to understand the antimalarials market, highlight gaps in knowledge requiring further research and emphasize the importance for countries, manufacturers and donors in having access to improved market data. Despite high mortality rates, malaria is a fact of life for many people across Africa, 40 - 60 % of whom seek treatment in the private sector. There is a thriving market for antimalarials in the private sector. Older classes of drugs are available even in remote areas. However, these classes (Chloroquine and SP) often face resistance, while newer classes have not replaced them in the private sector at local level. The antimalarials market in endemic countries is poorly understood and inadequately described. Detailed IMS-type data, outlining the different product types, market segments, pricing structures and supply chains simply do not exist. The lack of market data has implications for manufacturers, donors and national authorities in terms of clarifying total market, making credible forecasts, planning access through different outlet types, and securing required donor funding. New initiatives are underway to improve mapping of the antimalarials market. Medicines for Malaria Venture (MMV) brings together international players in the field of surveillance of the antimalarial market, focusing on non-commercial approaches to gathering and sharing data. By working together and using similar market survey methodologies, significant progress can be made to improve understanding of the size and structure of the antimalarials market in Africa.

Treating Malaria with Pyronaridine-Artesunate: Safety and Efficacy Results in Phase III Clinical Studies

7:00 pm - 8:15 pm
MMV Satellite Symposium session, Grand Ballroom A. Fifth Floor Sheraton New Orleans chaired by Co-chairs: Dr Antoinette Tshefu, University of Kinshasa & Dr Stephan Duparc, Medicines for Malaria Venture 
Description: Choices of safe, effective and affordable antimalarials are limited. The co-sponsors of the symposium, Medicines for Malaria Venture and their partner, Shin Poong Pharmaceuticals Ltd, are dedicated to developing high-quality medicines appropriate for those living in disease endemic countries. The speakers will focus on presenting and discussing the clinical results of three Phase III clinical trials of this novel ACT combination which were carried out in Africa and Asia: A) The safety and efficacy of a fixed dose combination of Pyronaridine/Artesunate tablets compared to artemether/lumefantrine in children and adult patients with uncomplicated P. falciparum malaria B) The safety and efficacy of a fixed dose combination of Pyronaridine/Artesunate granules (pediatric formulation) compared to artemether/lumefantrine crushed tablets in pediatric patients with uncomplicated P. falciparum malaria C) The safety and efficacy of a fixed-dose combination of Pyronaridine/Artesunate tablets compared to chloroquine in children and adult patients with uncomplicated P. vivax malaria.

8:00 am - 9:45 am 
Expanding ACT Reach in the Private Sector 
MMV Symposium session 60, Napoleon A123, 3rd floor Sheraton New Orleans 
chaired by Co-chairs : Dr Francisco Songane, Partnership for Maternal, Newborn and Child Health & George Jagoe, Medicines for Malaria Venture 
Description: Over 40% of the world’s inhabitants are at risk from malaria. Millions of children continue to fall prey to this dreaded disease. Among the many reasons for this unacceptable statistic is the fact that patients and caregivers have sorely limited access to high quality, effective treatment , particularly in private sector outlets where 40-60% of people buy their medicines. Are ACTs reaching people in Africa today? If not, why not? How can access to ACTs be facilitated? What are the challenges that must be overcome to ensure easy access of ACTs to malaria sufferers? Will a new, innovative mechanism in the form of a global subsidy ensure affordability, and thus access? What challenges still need to be overcome? Medicines for Malaria Venture (MMV) brings together international players in the field of access to antimalarials as well as representatives from national malaria programmes in Africa to share an overview of the status of access to effective antimalarials in Africa.

7:00 pm - 8:15 pm 
Dihydroartemisinin/Piperaquine: An innovative ACT in the treatment of P. falciparum malaria 
MMV Satellite Symposium session, Grand Ballroom A, Fifth Floor Sheraton New Orleans 
chaired by Co-chairs: Prof Nicholas White, Faculty of Tropical Medicine, Mahidol University & Dr Christopher Hentschel, Medicines for Malaria Venture 
Description: Malaria is a widespread disease prevalent in many developing countries. Dihydroartemisinin/Piperaquine (DHA + PQP) is a fixed-ratio drug combination developed to treat uncomplicated P. falciparum malaria. It can be given in a once a day dosing over three days. Here we report two Phase III comparative trials with DHA + PQP versus artesunate/mefloquine (AS+MQ), and artemether/lumefantrine (A+L), as well as the pharmacokinetics. These studies included over 2,500 patients in different epidemiological settings in Africa and Asia. The results demonstrate that DHA + PQP is an effective and well tolerated treatment for uncomplicated P. falciparum malaria, showing also significantly higher cure-rate at day 42 versus A+L and at day 63 versus AS+MQ. These findings, from one of the largest pivotal trials conducted for an innovative antimalarial, provide significant insights into the usage of ACTs in the treatment of uncomplicated P. falciparum malaria.

3:45 pm - 5:30 pm 
Progress and Challenges in Building an Antimalarial Drug Discovery Portfolio 
MMV Symposium 152, Gallery Ballroom, First Floor Sheraton New Orleans 
chaired by Co-chairs : Dr Winston Gutteridge, & Dr Timothy Wells, Medicines for Malaria Venture 
Description: Medicines for Malaria Venture (MMV), a product development partnership, is supporting a number of discovery research projects aimed at designing new drugs targeting novel mechanisms for the treatment and prevention of malaria. MMV supports individual research projects and the mini-portfolios of a number of R&D organizations. These exciting projects aim to discover completely new ways of attacking the parasite. The aim of the symposium is to demonstrate how molecular biologists, parasitologists, biophysicists, medicinal chemists and pharmacists work together to seek to achieve their goals through new thinking and cutting edge technologies. By illustrating how modern genomics, combinatorial chemistry and high throughput screening have revolutionised the process, we aim to push the research agenda to not only discovering novel ways of treating malaria but ultimately also to developing tools to eradicate it.